Serina Therapeutics, Inc. (SER) Stock Ticker
Market factors today
Unlock the full SER picture
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
SER stock facts
| Ticker symbol | SER |
| Exchange | New York Stock Exchange Arca |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market cap | $30.1M |
| CEO | Steven A. Ledger |
| Employees | 16 |
| Headquarters | Huntsville, AL, US |
| IPO date | 2018-11-28 |
| Website | serinatherapeutics.com |
What you can see for SER on Tickr
Live SER price chart with overlays, the options chain, implied move, IV rank, options flow and Strategy Lab, financial statements and consensus estimates, analyst ratings, catalysts, news with AI scoring, and an AI chat that has read the SER report.
Rankings
FAQ
What is the ticker symbol for Serina Therapeutics, Inc.?
The ticker symbol for Serina Therapeutics, Inc. is SER, listed on the New York Stock Exchange Arca.
What is SER?
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond…